Notification from a person closely related to a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration
Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements
Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022
